Background-In Crohn's disease, inflammation is presumably sustained by an
Recent studies have convincingly demonstrated that an increased release of proinflammatory cytokines by intestinal lamina propria mononuclear cells is involved in Figure) . Four patients stopped PTX treatment because of increased disease activity. None of the patients could discontinue prednisone during PTX treatment, five patients reduced prednisone by 5 mg daily, and five patients increased prednisone use. Overall, prednisone use on a cumulative basis was not changed significantly by PTX treatment (15 (4 68) before (n=16), versus 12 5 (2 5) after treatment (n= 12)).
Crohn's disease endoscopic index before and after treatment with PTX did not change significantly (14 9 (2 87) before treatment (n=16) versus 14 8 (2 27) after treatment (n=12), Figure) . All four patients who had to stop PTX treatment because of increased clinical activity, did have higher than average CDEIS scores at study begin (16 6 mean).
EFFECTS OF PTX ON FNFo. PRODUCTION
In six patients TNFcx secretion by peripheral monocytes was studied before and at the end of PTX treatment (35 8 (13 9) pg/ml before treatment versus 13 2 (19) after treatment, non-significant). All patients had detectable TNFoc production before PTX, in five patients it decreased below the sensitivity range, although in two patients values were already at the lower detection limit before PTX treatment. In one patient TNFot release was not inhibited by PTX.
Five healthy volunteers received oxpentifylline 400 mg four times daily for a period of two days. Release In contrast with anti-TNFt cA2 antibody treatment no effect by PTX could be seen on clinical, laboratory or endoscopic activity. With the exception of sleep disturbance by the disease, none of the social functions assessed by a questionnaire improved. However, upon a detailed interview most patients indicated retrospectively that improvement of sleep was due to reduced muscle aches and reduced night sweat. These are both symptoms that may be attributed to raised TNFa levels. 43 The negative results of PTX treatment suggest that the mechanism of anti-TNFot antibody treatment (using the monoclonal antibody cA223 24 It is not known how much suppression of TNFt is actually induced in the mucosal compartment by either cA2 anti-TNF antibody treatment or by PTX. Moreover, the possibility exists that a substantial proportion of mucosal TNFa originates from T cells, and inhibition of TNF production by mucosal T cell populations by PTX has not been investigated yet. Finally, although selection criteria were similar in both trials, Derxx et al23 24 investigated in their uncontrolled pilot study a more active patient population (as indicated by the higher average CDAI) than we did.
Therefore, patients' mucosal TNFa levels may have been different between both trials.
Further studies are necessary to clarify the relevance of mucosal TNFo production in the pathophysiology of inflammation in Crohn's disease. In this pilot trial, oxpentifylline at a dose of 400 mg four times daily given over a period of four weeks was not effective in treating patients with corticosteroid dependent chronic active Crohn's disease. Further controlled studies are warranted to examine the therapeutic potential of oxpentifylline and other TNFa inhibitors in Crohn's disease. 
